Cytek Biosciences Inc expected to post breakeven results a share - Earnings Preview

Cytek Biosciences

26/02/2024 23:39

* Cytek Biosciences Inc  CTKB.OQ   CTKB.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
28 for the period ending December 31 2023
    * The Fremont California-based  company is expected to
report a
17.1% increase in revenue to $56.583 million from $48.33 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Cytek Biosciences Inc is
for
breakeven results per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cytek
Biosciences
Inc is $11.00​, above​ its last closing price of $8.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.02        0.03       0.00      Missed  -103.3
 Jun. 30 2023  0.02        0.03       0.01      Missed  -66.7
 Mar. 31 2023  0.03        0.03       0.00      Missed  -100​
 Dec. 31 2022  0.05        0.05       0.06      Beat    28.6
 ​​Sep.        0.02        0.02       0.04      Beat    100
 30 2022                                                
 Jun. 30 2022  0.03        0.02       0.03      Beat    80​
 Mar. 31 2022  -0.01       0.00       0.01      Beat    300
 Dec. 31 2021  0.02        0.03       0.03      Met     20
 This summary was machine generated February 26 at 23:39 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)